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Abstract
Background: Double positive (DP) CD4CD8 Tab cells have been reported in normal individuals as well as in different
pathological conditions including inflammatory diseases, viral infections and cancer, but their function remains to be
elucidated. We recently reported the increased frequency of DP Tab cells in human breast pleural effusions. This manuscript
addresses the question of the existence and above all the role of this non-conventional DP sub-population among tumor
associated lymphocytes in melanomas.
Methodology/Principal Findings: We analyzed the intratumoral cell infiltrate in solid metastasis (n=6) and tumor invaded
lymph nodes (n=26) samples from melanomas patients by multiparametric cytometry. Here we documented for the first
time significant increased frequency of DP T cells in about 60% of melanoma tumors compared to blood samples.
Interestingly, a high proportion of these cells produced TNF-a in response to autologous melanoma cell lines. Besides, they
are characterized by a unique cytokine profile corresponding to higher secretion of IL-13, IL-4 and IL-5 than simple positive T
cells. In deep analysis, we derived a representative tumor-reactive DP T cell clone from a melanoma patient’s invaded lymph
node. This clone was restricted by HLA-A*2402 and recognized both autologous and allogeneic tumor cells of various
origins as well as normal cells, suggesting that the target antigen was a ubiquitous self antigen. However, this DP T cell
clone failed to kill HLA-A*2402 EBV-transformed B cells, probably due to the constitutive expression of immunoproteasome
by these cells.
Conclusions/Significance: In conclusion, we can postulate that, according to their broad tumor reactivity and to their
original cytokine profile, the tumor associated DP T cells could participate in immune responses to tumors in vivo. Therefore,
the presence of these cells and their role will be crucial to address in cancer patients, especially in the context of
immunotherapies.
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Introduction
In the last 20 years, T lymphocytes reactive to antigens
expressed by tumor cells have been shown to modulate cancer
development in animal models and human cancer patients [1,2].
Thus, much effort has been devoted to the development of
immunotherapeutic strategies aimed at inducing cancer regression
by enhancing antigen T cell responses [3]. Active (cancer vaccines)
and adoptive (infusion of tumor-reactive cells) immunotherapies
tested in clinical trials have produced tumor regression, proving
that the immune system can be harnessed to kill tumor cells in
cancer patients [4–6]. However, the efficacy of such strategies
remains quite limited and needs to be improved. It is now clear
that most cancer patients do not develop a satisfactory
immunological anti-tumor response due to the existence of
tumor-specific immune evasion strategies. Until now, several
mechanisms have been described including alteration of MHC
class I and tumor antigen expression by tumor cells, secretion of
immunosuppressive soluble factors either by tumor cells or
infiltrating T cells or both [7]. Recent studies have demonstrated
that one of the major mechanisms responsible for the downreg-
ulation of T-cell responses against tumors is the presence of several
types of suppressor cells within the tumor. These suppressor cells
include the now-classical T reg cells and the more recently
described type II NKT cells [8,9]. We hypothesized that insights
into these mechanisms could be gained from the study of T cell
infiltration in tumor and especially of unconventional and
regulator cell populations.
We previously reported in breast cancer patients that, in
addition to conventional CD4
+ and CD8
+ ab T cells, individual
tumors and most pleural effusions contained significant fractions of
unconventional double positive (DP) CD4
+CD8
+ ab T cells [10].
DP T cells have been reported as a small population in the
peripheral blood of healthy individuals, increasing with age [11].
PLoS ONE | www.plosone.org 1 January 2010 | Volume 5 | Issue 1 | e8437Furthermore, these cells may be increased in patients with
autoimmune diseases and viral infections [12–14]. They have also
been reported in cutaneous T-cell lymphoma and in nodular
lymphocyte predominant Hodgkin lymphoma [15,16]. Our earlier
study reported that the breast tumor associated DP T cells
displayed the phenotype and cytotoxic potential of effector/
memory activated CD8
+ T cells but differed essentially from these
cells by a high production of IL-4, IL-5 and IL-13 [10]. The
increased frequency of DP T cells in advanced breast cancer as
well as their high lytic potential and original cytokine profile
suggest that these cells might play a significant role in regulating
immune responses to human cancer. However, these breast cancer
associated DP T cells were not characterized with respect to anti-
tumor reactivity due to the difficulty of establish in vitro autologous
tumor cell lines in this model.
This led us to perform the current study in human melanomas
to determine the presence of DP T cells and their anti-tumor
reactivity. Examination of T cell subsets in metastasis and invaded
lymph nodes from melanoma patients revealed a significantly
increased proportion of DP T cells including autologous tumor-
reactive cells. We successfully isolated one autologous tumor-
specific DP T cell clone which has been characterized in terms of
functional properties and antigen specificity.
Results
Enhanced Frequencies of Tumor-Reactive DP T Cells in
Melanomas
We analyzed the intratumoral cell infiltrate in solid metastasis
(n=10) and tumor invaded lymph nodes (n=26) samples from
melanomas patients by flow cytometry. To get a sufficient number
of TAL (Tumor Associated Lymphocytes) for extensive charac-
terization, a single expansion of these cells was done using PHA
and feeder cells. For comparison purposes, a similar phenotypic
analysis was performed on fresh PBMC derived from healthy
donors (n=11) and from stage III melanoma patients (n=6). As
expected, most tumor infiltrating populations obtained after in
vitro expansion consisted of a majority of CD3 positive T cells
often exceeding 98%. As shown on Table 1, frequencies of SP
CD4
+ T cells were similar in PBMC and TAL whereas the CD8
+
subset was statistically higher in tumors, especially in invaded
lymph nodes (P,0.001). Significant fractions of DP T cells were
observed in about 60% of melanoma cases and represented 4.3%
of ILNL (Invaded Lymph Node Lymphocytes) and 9.5% of TIL
(Tumor Infiltrating Lymphocytes). In contrast, this population did
not exceed 1% in PBL from melanoma patients as well as in PBL
from healthy donors. The prevalence of DP T cells in metastatic
tumors was significantly higher (P,0.05) than in invaded lymph
nodes and still higher (P,0.01) than in normal or patients blood.
In order to evaluate their repertoire diversity, the pattern of
TCR Vb usage of four DP T cells populations was determined
with a panel of 24 anti-Vb antibodies representing the most
frequently expressed Vb chains within a normal repertoire
(Figure 1A). We showed that despite the strong dominance of
DP lymphocytes expressing one particular Vb chain (2, 11 or 13.2)
in two out of four melanoma invaded lymph nodes (M134 and the
M314), the repertoire analysis of these DP T cells populations was
relatively diverse and did not reveal any recurrence of a particular
Vb usage.
We then analyzed by flow cytometry the cytokine secretion
profile of DP T cells derived from solid tumors (n=4) and from
invaded lymph node (n=1) compared with SP CD4
+ and CD8
+ T
cells. Since results did not differ as a function of the TAL origin,
data were pooled in Table 2.
Mean fractions of TAL subsets secreting TNF-a and IFN-c
upon stimulation by anti-CD3 were similar. In contrast, the
percentages of IL-2, IL-4, IL-5, IL-13 and GM-CSF secreting cells
were higher among DP T cells than among SP T cells. This was
especially clear for IL-4 (P,0.05), IL-5 and IL-13 (P,0.001) with
respectively a mean of 40%, 21% and 75% of DP T cells secreting
these cytokines whereas these percentages did not exceed 23%,
5% and 35% in the SP subpopulations.
To evaluate the tumor reactivity of this new DP population, we
derived melanoma cell lines from tumor samples. The tumor
reactivity was evaluated by the percentages of SP CD8 and DP T
cells producing TNF-a in response to autologous melanoma cells.
Twenty one populations of short term culture TAL could be
analyzed and as shown on Figure 1B, more than fifty of these
contained a significant fraction (.2%) of autologous melanoma
reactive T cells among the DP population as well as among the SP
CD8 population. Moreover, the mean percentage of cells
producing TNF-a in response to autologous melanoma was
superior in DP T cells than in SP CD8 T cells (14.7% versus
4.7%).
DP T Cell Clone Selection and Characterization
To facilitate the characterization of the DP T cell population,
we derived tumor-reactive T cell clone from the M314 ILNL
population containing 14% of DP T cells among which about 60%
expressed the Vb13.2 TCR and were reactive against the
autologous melanoma cell line (Figure 2A). The Vb13.2 expressing
T cells were sorted by FACS and sequenced for CDR3 (data not
shown), that allow us to conclude that this Vb13.2 expressing sub-
population was clonal, hereafter referred to as M314.132. This
clone was TCRab CD4
lowCD8
high T cells and expressed a CD8ab
co-receptor.
The recognition of the autologous melanoma cell line by
M314.132 was inhibited by addition of W6/32 and B1.23.2 Abs,
showing that it occurs in the HLA class I context -B, -C or -A24
(Figure 2B). As illustrated by Figure 2C, this recognition was
dramatically reduced in the presence of a blocking anti-CD8
antibody, showing that this DP T cell clone was extremely CD8-
dependent but not at all CD4-dependent. Furthermore, TCR/
CD3 down-modulation induced after autologous melanoma
stimulation was observed confirming the implication of this
complex in DP T cell clone activation (Figure 2D).
Table 1. Distribution of T cells subsets based on CD3, CD4,
CD8 amongst melanoma patients PBMC and tumor associated









healthy donors (n=11) 70,5+/26,3 46+/210 9.5+/29 0.9+/20.6
melanoma patients (n=6) 68,5+/27,1 51.1+/261 4 . 9 +/23 0.6+/20.2
Melanoma Associated Lymphocytes
ILNL (n=30) 99,9+/20,2* 31.1+/226 54.2+/225*** 4.2+/25.6
TIL (n=10) 98,4+/29,1* 35,3+/226 50,3+/226** 9,5+/28,3**
Results are expressed as median fraction of cells expressing the marker(s) +/2
SD among total cells. Significant differences were evaluated by comparison
with similar cell fractions among melanoma cancer patient PBMC using the
Tukey-Kramer’s test. *P,0.05, **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0008437.t001
Tumor Reactive CD4CD8 T Cells
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analysis of the M314.132 clone. The clone was analyzed for the
production of a panel of cytokines after stimulation with
autologous melanoma cells. As shown in Figure 3A, the clone
produce high levels of IL-13, IL-4, TNF-a, GM-CSF, IL-2 and to
a lower extent IFN-c and IL-5. On the other hand, the clone does
not synthesize the suppressive cytokines IL-10 and TGF-b
(Figure 3A and data not shown). As illustrated by Figure 3B, the
clone M314.132 killed the M314 autologous melanoma cell line
but not the M132 allogeneic cell line used as negative control (no
common HLA with the patient). This lytic activity remains
relatively weak as shown by the percentage of lysis not exceeding
20% at an effector/target ratio of 50/1.
The DP T cell clone M314.132 expressed high levels of
CD45RO and lacked CD45RA, CD27, CD28, CD57and
CD62L suggesting the effector/memory phenotype of these cells
(Figure 3C).
We therefore analyzed the proliferative response of M314.132
to immobilized anti-CD3 mAbs. As shown in Figure 3D,
infiltrating melanoma DP T cell clone exhibited a very poor
proliferative response whereas CD8 SP T cell clone, used as
positive control, proliferated vigorously in response to the same
stimuli. The single positive CD8 T cell clone’s proliferation was
representative of those of all melanoma infiltrating CD8 T cells. In
addition to the lack of proliferation of this DP T cell clone in
response to CD3 activation, we failed to expand this clone using
the culture protocol used in our laboratory to expand single
positive CD8 (or CD4) T cell clones. We investigated, but so far
vainly, culture conditions to stimulate optimal proliferation of this
DP T cell clone by adding various combinations of cytokines on
top of IL-2 (IL-4, IL-7, IL-15 and IL-21) (data not shown). Finally,
the only method which let us to obtain a sufficient number of DP
clonal cells was a polyclonal expansion of infiltrating M314 lymph
Figure 1. Analysis of polyclonal DP T cells in melanoma: repertoire diversity and autologous-tumor reactivity. A/ Repertoire
diversity of DP T cells populations in tumors from four melanoma patients was assessed by labeling with 24 anti-Vb mAbs. Insets indicate the
percentage of the specific population characterized with this panel. B/ Percentage of TNF-producing cells in the SP CD8 and DP sub-populations in
response to the autologous melanoma cell line. The autologous tumor cells lines were established from metastatic lymph nodes of 21 melanoma
patients and were testedafter two at four weeks of culture initiation. 10
6 ILNL and2610
6 melanoma cells were incubated for 6 h in the presence of
Brefeldin A, stained with CD4 and CD8 mAbs, fixed, and stained with anti-TNF Ab in a permeabilization buffer. 10
5 cells were then analyzed by flow
cytometry.
doi:10.1371/journal.pone.0008437.g001
Table 2. Comparison of cytokine production capacities of DP




TNF-a 63+/212 79+/212 82+/210
IFN-c 32+/216 49+/229 46+/213
IL-2 28+/211 35+/217 48+/214
IL-4 22+/210 23+/254 0 +/211*
IL-5 2+/215 +/222 1 +/27***
IL-13 28+/210 35+/211 75+/212***
GM-CSF 48+/222 53+/222 74+/211
Data are expressed as mean % of intracellular cytokine secreting cells in
response to anti-CD3 stimulation (n=5). Significance increase of cytokines
production by DP T cells was evaluated by Tukey-Kramer’s test.
*P,0.05,***P,0.001. No cytokine production was observed by unstimulated
subpopulations.
doi:10.1371/journal.pone.0008437.t002
Tumor Reactive CD4CD8 T Cells
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cells corresponding to the M314.132 DP T cell clone.
HLA-A*2402 Restriction and Recognition of Various
Tumors by DP T Cell Clone
To precisely define the HLA restriction and to establish the
distribution of the target antigen, we tested M314.132 reactivity
towards various tumor cell lines, including melanomas, colon
carcinomas, breast carcinomas, renal carcinomas, ovarian carci-
nomas, lung carcinomas and myelomas, using a TNF-release
assay. As shown in Figures 4A and B, this clone recognized all of
the melanoma and other tumor cell lines tested expressing the
HLA-A*2402 molecule. All tumor cell lines which are not
recognized by the DP T cell clone do not express the HLA-
A*2402 and/or 2301 molecules. Nevertheless, the production of
TNF is lower upon stimulation by the tumor cell lines other than
melanomas. This result was in accordance with the inhibition of
tumor reactivity observed with B1.23.2 antibody cross-reacting
against the HLA-A*2402 (Fig. 2B). In addition, the M314.132 DP
T cell clone recognized tumor cell lines expressing the closest
matched allele HLA-A*A2301. To complete this study, we
transfected a large panel of tumor cell lines by HLA-A*2402
coding cDNA, comprising a variety of cell types as melanomas,
breast carcinomas, renal carcinomas, ovarian carcinoma, myelo-
ma and glioblastomas (Figure 4C). All the cell lines transfected
with the HLA-A*2402 were recognized according to the
transfection’s efficiency evaluated by GFP transfection control
(data not shown). These data lend support to the recognition by
the DP T cell clone M314.132 of a common antigen presented on
HLA-A*2402/2301 by cancer cells of different histological origins.
Recognition of Various Normal Cells Except Lymphocytes
by DP T Cell Clone
To address the question of tumor antigen specificity, we
tested the recognition of normal cells from various types.
First, M314.132 DP T cell clone recognized HLA-A*2402
positive melanocytes (Mela1) but none of the two non-HLA-
A*2402 melanocytes (Figure 5A). However, this reactivity was
much lower than that observed against melanoma cell lines.
Moreover, diverse normal cell lines including human adipo-
cytes, fibroblasts and embryonic kidney cells as well as african
green monkey kidney cells were recognized after HLA-A*2402
transfection (Figure 5B). Nonetheless, the six EBV-B cell lines
tested were not recognized by M314 DP T cell clone even the
three HLA-A*2402 homozygous cell lines. As EBV-transformed
B cell lines have been shown to express the immunoproteasome
constituvely [17], we reasoned that if the lack of recognition of
homozygous HLA-A*2402 EBV-B cell lines by DP T cell clone
was due to their constitutive expression of immunoproteasome,
then tumor cells should also lose expression of the epitope after
prolonged treatment with IFN-c. M314 autologous melanoma
cell line was treated with IFN-c for 15 days before being tested
for recognition by the clone. As shown in Figure 5D, we
observed an inhibition of DP T cell clone recognition. Two
CD8 T cell clones were used as controls, one specific for the
MELAN-A26–35 epitope which is not processed by immuno-
proteasome and one specific for the MELOE-136–44 epitope
which is processed by both standard proteasome and immuno-
proteasome.
Overall, the M314.132 clone seems to recognize a ubiquitous
self antigen processed by the standard proteasome and presented
Figure 2. DP T cell clone selection and characterization. A/. Distribution of CD3
+ T cells subsets based on CD4, CD8 in the M314 ILNL
population. Lymphocytes were analyzed after in vitro expansion by three-color flow cytometry using antibodies specific for CD3, CD4 and CD8a
or CD8b.P e r c e n t a g eo fV b13.2 TCR expressing cells was examined on gated the 14% of DP T cells. The Vb13.2 TCR expressing cells DP T cells were
then sorted by FACS. B and C/ TNF secretion by the M314.132 DP T cell clone in response to the autologous melanoma cell line. 10
4 DP T cells
were added to 3610
4 M314 melanoma cells in the presence or not of blocking antibodies directed against class I (W6/32), B/C/A24 (B1.23.2), class
II (206) HLA and against CD4 and CD8 molecules at the indicated dilutions or concentrations. DP T cell clone reactivity was assessed by a TNF
release assay. D/ Time course of CD3 (white) and TCR (black) down-regula t i o ni nM 3 1 4 . 1 3 2D PTc e l lc l o n es t i mulated with autologous melanoma
cell line.
doi:10.1371/journal.pone.0008437.g002
Tumor Reactive CD4CD8 T Cells
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from different species.
Discussion
The current report provides for the first time functional
evidence of tumor reactivity of CD4
+CD8
+ DP Tab cells in
human melanomas. We first observed statistically enhanced
frequencies of DP T cells compared to metastasis melanomas
(P,0.05) and in invaded lymph nodes (P,0.01) than in normal or
patients blood. So, as we previously documented in breast cancer
patients [10], this increase of DP T cells is associated with tumor
microenvironment. Others studies also reported an increased
number of DP T cells in lymphomas [16] and in other diseased
individuals [18–20].
Of interest, the presence of DP T cells in the target organ of
several auto-immune conditions reinforces their involvement in
pathologically relevant events. Yet, in humans, very little is known
Figure 3. Functional properties of the M314.132 DP T cell clone. A/ Cytokine production analysis. DP T cell clone was fixed, permeabilized
and stained for cytokines following autologous melanoma stimulation. Data are expressed as mean % of intracellular cytokine secreting cells. Open
histograms correspond to the analysis of cytokine production by unstimulated M314.132 DP T cell clone (negative control). B/Lysis of the M314
autologous melanoma cell line (closed circles) by M314.132 DP T cell clone. The M132 cell line was used as negative control target (open circles).
51Cr-labeled tumor cells were co-cultured with T cells at various E/T ratios. Chromium release in the supernantants was measured after a 4-h
incubation period. C/ Phenotypic characterization of M314 DP T cell clone. D/ Proliferation capacity. CFSE-labeled T cell clones were stimulated with
anti-CD3 (OKT3). The CD8 T cell clone used as positive control was obtained by limiting dilution of melanoma specific CD8 T cells. As negative control,
T cell clones were maintained in the absence of any stimulation (Not Stimulated: NS).
doi:10.1371/journal.pone.0008437.g003
Tumor Reactive CD4CD8 T Cells
PLoS ONE | www.plosone.org 5 January 2010 | Volume 5 | Issue 1 | e8437about their antigen specificity and their function. CMV and HIV-
1 viral antigen-specific cytotoxic and proliferation responses of DP
cells have been observed demonstrating their effector status
[21–23]. In tumors, there is only one report showing that DP T
cells infiltrating a cutaneous T cell lymphoma exert a tumor-
specific MHC class-I restricted lysis [15]. Interestingly, our study
showed that about 15% of polyclonal melanoma infiltrating DP T
cells produce TNF-a in response to autologous tumor cells,
demonstrating the frequent anti-tumor reactivity of this new sub-
population. This percentage was higher than those observed with
SP CD8 suggesting their physiological relevance in tumors.
To further study the phenotype and the function of tumor
infiltrating DP T lymphocytes, we isolated a DP T cell clone from
invaded lymph node of melanoma patient M314, in which these
sub-population represents about 14% of TIL. This DP Tab
cell clone namely M314.132, co-expressed the CD4
lo and the
CD8
hiab receptors and displayed an effector memory phenotype.
M314.132 DP T cell clone recognized autologous melanoma
cells in MHC class I restricted context with a very strong CD8
dependence. In response to autologous melanoma cell line, this
clone is lytic and produced in decreasing order the following Th1
and Th2 cytokines: IL-13, IL-4, TNF-a, GM-CSF, IL-2, IFN-c
and IL-5. This original cytokinic profile was also observed on
polyclonal melanoma infiltrating DP T cells in response to CD3
stimulation and was similar on polyclonal breast tumor associated
DP T cells as we previously reported [10]. In comparison to SP T
cells, DP T cells have much greater capacity to produce Th2
cytokines, especially regulatory cytokines such as IL-13 (75% of
cytokines secreting cells), IL-4 (40%) and IL-5 (21%). Terabe and
Berzofsky single out IL-13, produced by type II NKT cell in
several mouse tumor models, as an important immunosuppressive
cytokine, inducing CD11b
+Gr-1
+ myeloid lineage to secrete TGF-
b that finally inhibits CTL induction against the tumor [8,24,25].
It has also been reported that human CD4
+ regulatory NKT cells
can suppress the expansion of tumor antigen-specific CTLs via
Th2 cytokines such as IL-4 and IL-10 [26]. In addition, it has been
documented that IL-13 and IL-4 downregulated arginase
production in melanomas, leading to down-regulation of CD3f
expression thus limiting T cell function [27]. In contrast, another
study reported that the massive production of IL-4 and IL-13 by
the CD4 subset of invariant NKT, together with IFN-c, induced
IL-12 production by the dendritic cells leading to a shift toward
Th1 responses [8,28]. The last cytokine specifically produced by
DP T cells, IL-5, is generally regarded as a Th2 cytokine involved
in eosinophil maturation and function and in B cell growth and
antibody production. However, Apostolopoulos and collaborators
have demonstrated in vivo in a mouse model the role of IL-5 in the
generation of a functional cytotoxic response to tumors [29].
Moreover, high amounts of IL-5 have been shown to be produced
by a fraction of human CD4
+ invariant NKT [30]. Therefore,
considering their cytokinic profile, it is conceivable that melanoma
infiltrating DP T cells might play, at the effector level, roles similar
to those of regulatory invariant NKT.
One major difference between SP T cells and DP T cells in vitro
is the limited capacity to divide displayed by DP T cells. This poor
proliferative capacity could be due to short TREC (T cell
Receptor Excision Circles) levels. Indeed, it has been reported that
DP T cells displayed lower TREC content than SP cells,
demonstrating at the molecular level that DP T cells experienced
more cells divisions than their SP counterparts [21].
With regard to antigen specificity of DP T cells, we show that
M314.132 clone, which was restricted by HLA-A*2402 (and the
very similar HLA-A*2301 allele), recognized both tumor and
normal cells from different origins. We speculated that the target
antigen could be a ubiquitous self-antigen. The recognition of
ubiquitous self antigens by tumor infiltrating CD8 T lymphocytes
has already been described in renal and prostate cancers [31,32].
On account of their abundant and ubiquitous nature, these
antigens may represent a new type of tumor-associated antigens.
Hypothetically, these antigens would be derived from ubiquitously
expressed proteins that, under normal circumstances, are not
efficiently processed. However, despite the probable expression of
Figure 4. Reactivity of M314.132 DP T cell clone against tumor
cell lines. A and B/ TNF secretion by the M314.132 DP T cell clone in
response to tumor cell lines. 10
4 DP T cells were added to 3610
4 M314
melanoma cells (A) or other tumor cells (B). All tumor cell lines which
are not recognized by the DP clone do not express the HLA-A*2402
and/or 2301 molecules. C/ TNF secretion by the M314.132 DP T cell
clone to HLA-A*2402 transfected tumor cells. Melanoma (n=10), breast
carcinoma (n=2), renal carcinoma (n=1), ovarian carcinoma (n=1),
myeloma (n=1), and glioblastoma (n=3) cell lines were transiently
transfected with 100ng of HLA-A*2402 plasmid with a lipofectamine
reagent kit. 10
4 DP T cells were added to 3610
4 target cells, and the DP
T cell clone reactivity was assessed by a TNF release assay. Results are
expressed as relative reactivity to the indicated cells in comparison with
TNF secretion (100%) induced by M314 autologous melanoma cells.
doi:10.1371/journal.pone.0008437.g004
Tumor Reactive CD4CD8 T Cells
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not recognized by the DP T cell clone. In addition, we observed an
inhibition of DP T cell clone recognition of IFN-c long-pretreated
autologous melanoma cells, which could be attributed to the
replacement of the standard proteasome by the immunoprotea-
some. This observation additionally supports our hypothesis that
although EBV-B cells express ubiquitous self Ags, they are not
capable of processing the epitope recognized by the DP T cells due
to their constitutive expression of immunoproteasome. A major
difference between the two forms of proteasomes in terms of
catalytic activity is the severely reduced ability of the immuno-
proteasome to cleave after acidic residues and after residues with
branched side chains [33–35]. This last point could explain why
Melan-A as RU1, gp100 and tyrosinase epitopes having a valine at
their C terminus are not cleaved by the immunoproteasome
[31,36]. This could also be the case for HLA-A*2402 epitopes for
which branched amino acids as leucin or isoleucin have been
reported among their predictable anchor sites. The notion that the
immunoproteasome is more competent at producing class-I-
binding peptides probably remains true for many epitopes.
However a number of epitopes, mainly derived from self proteins,
are not processed efficiently by the immunoproteasome. This
provides a plausible explanation for DP T cells escape negative
selection in the thymus where a high level of immunoproteasome
has been observed [37]. It could also explain why such cells did not
undergo autoimmune activation, again because mature dendritic
cells, which are considered as the major antigen-presenting cells
capable of activating naive T cells, only carry immunoproteasomes
[38].
Concerning the origin of DP T cells, several studies hypothe-
sized that they could derive from SP cells. It has been
demonstrated that IL-4 represents an important soluble mediator
of CD8aa induction on human SP CD4 T cells [39]. On the other
hand, when activated in vitro via TCR cross-linking, SP CD8ab T
cells may become capable of expressing low levels of CD4 [40].
Nevertheless, M314.132 clone as well as polyclonal DP T cells
were found to express high levels of both CD4 and CD8ab
molecules during all time of culture, ruling out the hypothesis of
the acquisition of a second CD4 or CD8 co-receptor. Moreover,
the M314.132 DP T cell clone, representing more than 60% of the
M314 DP T cell subset expressed the Vb13.2, which is not used by
the M314 SP T cell subsets (data not shown). Therefore, as judged
by their TCR Vb usage, and in accordance with earlier studies on
DP T cells present in lesional skin of patients with systemic
Figure 5. Reactivity of M314.132 DP T cell clone against normal cell lines. A/ TNF secretion by the M314.132 DP T cell clone in response to
melanocytes. 10
4 DP T cells were added to 3610
4 HLA-A*2402 positive or negative melanocytes, and the clone reactivity was assessed by a TNF
release assy. B/ TNF secretion by the M314.132 DP T cell clone to HLA-A*2402 transfected (+) or non-transfected (2) normal cells of different origins
and/or species. Results are expressed as relative reactivity to the indicated cells in comparison with TNF secretion (100%) induced by M314
autologous melanoma cells. C/ Lack of recognition of HLA-A*2402 EBV-B lymphocytes. DP T cell clone was fixed, permeabilized and stained for
cytokines following stimulation with EBV-B cell lines expressing or not HLA-A*2402 molecules. Data are expressed as mean % of intracellular TNF-a
secreting cells. D/ TNF response of DP T cell clone toward melanoma cells treated with or without IFN-c. Melanoma cells were cultured in the
presence or absence of 100U/ml rIFN-c for 15 days. DP T cell clone and two CD8 T cell clones used as controls were fixed, permeabilized and stained
for TNF following stimulation with untreated (white bars) or IFN-c-treated (hatched bars) melanoma cells. Data are expressed as mean % of
intracellular TNF-a secreting cells.
doi:10.1371/journal.pone.0008437.g005
Tumor Reactive CD4CD8 T Cells
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origin distinct from that of SP CD4
+ and CD8
+ SP cells [13].
Another question concerns the increase of the frequencies of DP
T cells in some tumors. In previous studies, the higher expression
of CXCR3 and CCR6 chemokines receptors on DP T cells
compared to SP T cells have been described that could explain
their recruitment in tumors [12,41]. Nonetheless, we observed that
M314.132 DP T cell clone express poorly CCR6 and not at all
CXCR3 (data not shown). The molecules and cytokines involved
in the recruitment and/or propagation of DP T cells in
melanomas have to be clearly identified.
In conclusion, although the function of this DP T cell
population remains to be defined in vivo, we can postulate that,
according to their broad tumor reactivity and to their cytokinic
potential, these cells could participate in immune responses to
tumors. The clinically relevant function of these tumor associated




The phenotype of cells was analyzed using monoclonal
antibodies (mAbs) in conjunction with three or four color
immunofluorescence. The mAbs used in this study include
fluorescein isothiocyanate (FITC)-, phycoerythrin (PE)-, allophy-
cocyanin (APC)-, peridin-chlorophyll-protein complex (PerCp)-
conjugated reagents against CD3, CD4, CD27, CD28, CD45-
R A ,C D 4 5- R O,C D 57 ,C D 62 - L ,I L - 2 ,IL - 4,IL - 5 ,I L - 1 3,T N F - a,
IFN-c, GM-CSF from BD Biosciences, CD8a,C D 8 b,T C R ab,
Vb1, -2, -3, -4, -5.1, -5.2, -5.3, -7, -7.2, -8, -9, -11, -12, -13.1, -
13.2, -13.6, -14, -16, -17, -18, -20, -21.3, -22, and -23, from
Beckman Coulter. mAbs used for blocking experiments against
HLA class I (clone W6.32), HLA-B/C (clone B1.23.2), HLA class
II (clone 206) were produced in our laboratory from hybridomas
obtained from the American Type Culture Collection for W6.32
A ba n df r o mF .L e m o n i e r( P a s t e u rI n s t i t u t e ,P a r i s ,F r a n c e )f o r
B1.23.2 Ab.
Patients and Specimens
Peripheral blood (n=6), metastasis (n=10), invaded lymph
nodes (n=30) were collected from patients with melanoma and
peripheral blood (n=11) from healthy donors, all with formal
consent.
Ethics Statement
Written consents were obtained from all patients and healthy
donors. All these studies were approved by the local ethics
committee ‘‘Comite ´ de Protection des Personnes Ouest IV-
Nantes’’ and the ‘‘Agence franc ¸aise de se ´curite ´ sanitaire des
produits de sante ´’’.
Isolation of Polyclonal Cell Populations (TIL, ILNL and
PBMC)
Solid tumor fragments of primary tumor or tumor invaded
lymph node were mechanically disaggregated. Tumor Infiltrating
Lymphocytes (TIL) and tumor Invaded Lymph Node Lympho-
cytes (ILNL) were isolated by culturing disaggregated tumor
fragments into 24-well tissue culture plates with RPMI 1640
(Sigma-Aldrich) containing 8% human serum (local production),
100U/mL penicillin, 100mg/mL streptomycin (Sigma-Aldrich),
2mM L-glutamine (Sigma-Aldrich) and 150U/ml rIL-2 (Euro-
cetus, Rueil-Malmaison, France) for 10–14 days. These popula-
tions were then expanded by a single round of stimulation with
PHA-L (Sigma-Aldrich) in the presence of irradiated feeder cells
(allogeneic lymphocytes and B-EBV B cells), as described [42,43].
The expanded lymphocytes were transferred into 6-well tissue
culture plates with fresh medium to maintain a cell density of 0.5
to 1.5610
6 cell/mL.
PBMC (Peripheral Blood Mononuclear Cells) were isolated
from blood by a Ficoll density gradient (Eurobio, Les Ulis, France).
Sorting DP T Cell Clone M314.132 with Facs Aria
First, polyclonal lymphocytes from M314 patient were labeling
with Vb13.2 mAb following a standard cell surface staining
procedure. The sorting was performed on a Facs Aria (Becton
Dickinson, Grenoble, France). Gates were set up to exclude
nonviable cells and debris. Sorted DP T cell clone was assessed to
ensure its purity.
Cell Lines Culture
Melanoma cells lines, colorectal carcinoma cell line C4-A and
renal carcinoma cell lines (R3 and R9) were established,
respectively, in the GMP Unit of Cellular Therapy and in our
laboratory. Mouse fibrosarcoma WEHI 164 clone 13 (established
by M. Rollinghoff and N.L. Warner) and COS-7 cells (established
by Y. Gluzman) were obtained from T. Boon (Ludwig Institute for
Cancer Research, Brussels, Belgium). Ovary carcinoma cell line
(OVCAR-3) (established by T.C. Hamilton), renal carcinoma cell
line (A498) (established by D.J. Giard) and non-small cell lung
cancer cell line (1355) (established by H. Oie) were gifts from C.
Saı ¨ (UMR 892 INSERM/Universite ´ de Nantes, France). Colo-
rectal carcinoma cell lines, LS174T and LS180 (established by
B.H. Tom), SW480 (established by J. Fogh), SW707 (obtained
from the DKFZ tumor bank), SW1116 (established by W.C.
Wright), glioblastoma cells lines, U-251 (established by D.D.
Bigner), GBMS1 and GBS (established by M. Gregoire), and HFF-
2 fibroblast cell line (established by ATCC) were gifts from M.
Gre ´goire (UMR 892 INSERM/Universite ´ de Nantes, France).
Myeloma cells lines, XG-7 (established by X.G. Zhang), KMM1
(established by Dr Otsuki), NCI-H929 (established by G.F. Hollis),
OPM-2 (established by Dr Katagiri), LP1 (established by Dr
Pegoraro) were gifts from C. Pellat (UMR 892 INSERM/
Universite ´ de Nantes, France). Breast cancer cell lines, CAMA-1
(established by J. Fogh), MDAMB-231 and MDAMB-468
(established by R. Cailleau) were gifts from D. Ja ¨ger (Klinik und
Poliklinik fu ¨r Onkologie, Zu ¨rich, Suisse). Breast cancer cell line
S68 was established and gift from V. Catros (UPRES EA, 3891,
Rennes, France). Breast cancer cell line MCF-7 (established by B.J.
Sugarman), was obtained from the American Type Culture
Collection. Normal melanocytes were established and gifts from
M. Regnier (L’Ore ´al Laboratory, Paris, France). EBV-B cell lines
were established and gifts from C. Reutie `re (EFS, Nantes, France).
Human adipocytes PAZ-6 (established by V. Zilberfarb) were a
gifts from J-P. Segain (UMR 1280 INRA/Universite ´ de Nantes,
France).
T Cell Clones
Melanoma-reactive CD8 ab T cell clones specific for Melan-A/
MART-1 (AAGIGILTV) and MELOE-1 (TLNDECWPA) epi-




5 cells were stained with isotype controls or with one or
four antibodies for 20 minutes at 4uC. Cells were then washed and
10
5 cells were acquired in the viable cells gate on a FACScalibur
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Grenoble, France).
Transient Transfection of Cell Lines by the HLA-A*2402
cDNA
The HLA-A*2402 cDNA was cloned from the M314 melanoma
cell line. Cells were seeded in 96-well plates and incubated until
they were 80% confluent. The expression plasmid carring the
HLA-A*2402 cDNA (100ng) was mixed for 30 minutes with
Reagent Plus (1ml), Lipofectamine Reagent (0.5ml) in 20mlo f
Optimem I medium (Life Technologies). Cells were washed by
replacing the complete medium by the Optimem I medium (50ml).
Then, the HLA-A*2402/Lipofectamine mix was added in each
well. After 3 hours of incubation, complete medium (130ml) was
added to the transfection mixture.
Analysis of TNF Production
Measurement of TNF produced by T cells in response to tumor
cells or transfected tumor cells was performed as previously
described, using WEHI 164 clone 13 cells [44]. For blocking
experiments, melanoma cell lines or DP T cell clone were pre-
incubated with different Abs.
Analysis of Intracellular Cytokines by Flow Cytometry
Lymphocytes were stimulated by OKT3 (5mg/mL, Clinis-
ciences) or tumor cells, in 200ml of RPMI 1640-10% FCS in the
presence of Brefeldin A, 10mg/ml (Sigma, St Louis MO, USA) for
cytokine analysis in round-bottom 96-well plates. The cultures
were incubated for 6 hours at 37uCi n5 %C O 2 humidified
atmosphere. Cells were then stained at 4uC for 20 minutes, with
anti-CD4 and anti-CD8 Abs for extracellular staining. For
intracytoplasmic staining, cells were washed two times in 0.1%
PBS BSA, fixed 10 minutes at room temperature in a solution of
PBS 4% paraformaldehyde (Sigma), washed again and stored at
4uC until labeling. Specific mAbs (cytokines) were added to fixed
cells and incubated for 30 minutes at room temperature. Reagent
dilutions and washes were made with PBS containing 0.1% BSA
and 0.1% saponin (Sigma). After staining, cells were resuspended
in PBS and 10
5 viable cells were acquired on a FACScalibur
cytometer using Cellquest software. According to the FSC/SSC
parameters, lymphocytes were gated and the autologous melano-
ma cells were excluded. using Cell Quest Pro software.
Analysis of Lytic Activity
Cytotoxic activity of T cells was measured in a standard 4-h
assay against
51Cr-labeled cells. Briefly, tumor cell lines were
labeled with 100mCi Na
51CrO4 (Oris Industrie, Gif-sur-Yvette,
France) for 1h at 37uC, and incubated, 4h at 37uC, with effectors
T cells at various ratios. The radioactivity, released by target cells,
was measured on a beta plate counter (EG&G Wallac, Evry,
France).
CD3 and TCRab Downregulation
CD3 or TCRab fluorescence intensity was measuring in
unstimulated and activated lymphocytes with tumor cells following
a standard cell surface staining procedure. Data were expressed as
percentages of cells showing a CD3 and TCRab downregulation.
Proliferation Assay
Lymphocytes were labeled with CFSE (Sigma-Aldrich) as
described previously [45]. The 5 mM stock solution of CFSE in
DMSO (Sigma-Aldrich) was diluted to 5 mM in a volume of PBS
equal to that in which cells (1610
7 cells/ml in PBS) were
suspended, and the cells were then incubated at 37uC for 10 min.
The labeling process was quenched by adding an equal volume of
heat-inactivated FBS (Invitrogen) to the sample. After 1 min,
CFSE-labeled cells were washed three times, recounted, and
adjusted to a concentration of 5610
5 cells/ml in the culture
medium. 10
5 CFSE-labeled lymphocytes were then incubated with
200ml RPMI 1640-8% SH and 150U/ml rIL-2 in round-bottom
96-well plates in the presence or absence of OKT3 (5mg/mL,
Clinisciences). After 5 days, cells were suspended in PBS/BSA and
tested for fluorescence using a Becton Dickinson FACSCalibur
with CellQuest
TM Pro. FACS data and CFSE intensity were
analyzed using FlowJo (version 7, Tree Star, Inc. Oregon, USA).
In this experiment, a single positive CD8 T cell clone, obtained by
limiting dilution of melanoma specific CD8 T cells, was used as
positive control of proliferation.
Statistical Analysis
Statistical analysis was done with InStat 2.01. Data were
analyzed using Tukey-Kramer multiple comparisons test. P,0.05
was considered significant.
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